EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Postmarketing Assessment of Antibody–Drug Conjugates: Proof‐of‐Concept Using Model‐Based Meta‐Analysis and a Clinical Utility Index Approach

Innocent Gerald Asiimwe iD, Nour Chtiba, Samer Mouksassi iD, Goonaseelan Colin Pillai iD, Raimund M Peter iD, Eunice Yuen iD, Venkatesh Pilla Reddy iD

CPT: Pharmacometrics & Systems Pharmacology · 2025-11 · 14 (11) · 1810-1822

DOI: 10.1002/psp4.70013 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 04.03.2025. Verfasst von Innocent Gerald Asiimwe und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Wolfson Centre for Personalized Medicine, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, U…. Hauptthemen laut MEDLINE: Ado-Trastuzumab Emtansine, Antineoplastic Agents, Immunological, Immunoconjugates, Trastuzumab. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody–drug conjugates (ADCs) are a promising class of targeted cancer therapies. However, they need careful dose optimization to maximize effectiveness and minimize side effects. Sometimes, safety issues may only become apparent after approval, so ongoing evaluation is important. This study aimed to assess the benefit–risk profiles of two approved trastuzumab–drug conjugates: trastuzumab emtansine (T‐DM1) and trastuzumab deruxtecan (T‐DXd). A systematic search of MEDLINE on May 1, 2024, identified clinical trials reporting the pharmacokinetics, pharmacodynamics, safety, and efficacy of T‐DM1 and T‐DXd. Summary‐level data from 103 trials was used along with model‐based meta‐analysis to develop population pharmacokinetic and exposure–response models for both ADCs. The study combined the objective response rate (ORR) and dose‐limiting toxicity (DLT) into a composite score called the clinical utility index (CUI) to determine optimal drug exposures and doses that maximize the benefit–risk balance. Different ORR/DLT weights and CUI thresholds representing desired minimum effect size were tested in three scenarios (“only phase I trials,” “phase I/II trials,” and “all phases”). Using a CUI threshold of 10%, the approved T‐DM1 dose of 3.6 mg/kg for breast cancer was found to align with an efficacy–safety (ORR‐DLT) ratio of 81:19 with all phases. Applying these weights to the T‐DXd analyses successfully predicted the approved T‐DXd dose (5.4 mg/kg, breast cancer), showing a CUI improvement compared to the 3.2 mg/kg dose of 8.3%, 8.2%, and 2.4% in the three respective scenarios. Overall, this proof‐of‐concept assessment of ADCs can save time and costs for pharmaceutical companies and optimize dosing to maximize patient benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ado-Trastuzumab EmtansineAntineoplastic Agents, ImmunologicalImmunoconjugatesTrastuzumabHumansBreast NeoplasmsDose-Response Relationship, DrugModels, BiologicalProduct Surveillance, PostmarketingProof of Concept StudyCamptothecin

Stichwörter der Autor:innen

antibody–drug conjugatesclinical utility indexmodel‐based meta‐analysistrastuzumab deruxtecantrastuzumab emtansine

Substanzen

Ado-Trastuzumab EmtansineAntineoplastic Agents, ImmunologicalImmunoconjugatesTrastuzumabtrastuzumab deruxtecanCamptothecin

Autor:innen und Institutionen

  • The Wolfson Centre for Personalized Medicine, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
  • APT-Africa Fellowship Program, c/o Pharmacometrics Africa NPC, Groote Schuur Hospital, Cape Town, South Africa.
  • Pharmacy of Monastir, University of Monastir, Monastir, Tunisia.
  • Certara, Cairo, Egypt.
  • Division of Clinical Pharmacology, University of Cape Town, South Africa.
  • CP+ Associates GmbH, Basel, Switzerland.

ORCID-Profile: Innocent Gerald Asiimwe, Samer Mouksassi, Goonaseelan Colin Pillai, Raimund M Peter, Eunice Yuen, Venkatesh Pilla Reddy

Zitieren

APA

Asiimwe, I. G., Chtiba, N., Mouksassi, S., Pillai, G. C., Peter, R. M., Yuen, E., & Pilla Reddy, V. (2025). Postmarketing Assessment of Antibody–Drug Conjugates: Proof‐of‐Concept Using Model‐Based Meta‐Analysis and a Clinical Utility Index Approach. CPT: Pharmacometrics & Systems Pharmacology, 14(11), 1810-1822. https://doi.org/10.1002/psp4.70013

Vancouver

Asiimwe IG, Chtiba N, Mouksassi S, Pillai GC, Peter RM, Yuen E, et al. Postmarketing Assessment of Antibody–Drug Conjugates: Proof‐of‐Concept Using Model‐Based Meta‐Analysis and a Clinical Utility Index Approach. CPT: Pharmacometrics & Systems Pharmacology. 2025;14(11):1810-1822. doi:10.1002/psp4.70013

BibTeX
@article{Asiimwe2025,
  author = {Asiimwe, Innocent Gerald and Chtiba, Nour and Mouksassi, Samer and Pillai, Goonaseelan Colin and Peter, Raimund M and Yuen, Eunice and Pilla Reddy, Venkatesh},
  title = {Postmarketing Assessment of Antibody–Drug Conjugates: Proof‐of‐Concept Using Model‐Based Meta‐Analysis and a Clinical Utility Index Approach},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2025},
  volume = {14},
  number = {11},
  pages = {1810--1822},
  doi = {10.1002/psp4.70013}
}
Kostenlos starten →